Literature DB >> 27117448

Development and validation of the Patient Benefit Index for the dermatocosmetic treatment of aged skin.

David Lohrberg1, Jürgen Blaak2, Juliane Liebsch3, Peter Staib2, Rainer Wohlfart2, Dieter Lüttje4, Nanna Y Schürer3, Matthias Augustin5, Christine Blome5.   

Abstract

This study aimed to develop and validate an instrument for the assessment of patient-relevant benefit in dermatocosmetic treatment, i.e., skin care, of aged skin. Based on an open item collection with 33 elderly persons, items on patient-relevant treatment goals were collected. An expert panel selected 20 items to be most relevant and feasible for the questionnaire named Patient Benefit Index for Aged Skin (PBI-AS). The instrument, which assesses goal importance and achievement, was tested in a cognitive debriefing and validated in a longitudinal study (n = 80) along with the Dry Skin Area and Severity Index (DASI) and the Dermatology Quality of Life Index (DLQI) as convergent validation criteria. The cognitive debriefing showed the good practicability and feasibility of the instrument. Significant correlation with change in DASI (r = -0.527; p < 0.001) supports convergent validity of the PBI-AS. By contrast, correlation with DLQI was poor, indicating the different constructs. The PBI-AS is a valid and feasible tool for the patient-centered assessment of dermatocosmetic treatment benefit in aged skin.

Entities:  

Keywords:  Aged skin; Dermatocosmetic treatment; Patient-relevant benefit; Quality of life; Validation

Mesh:

Year:  2016        PMID: 27117448     DOI: 10.1007/s00403-016-1648-5

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  1 in total

1.  Identifying Epidermolysis Bullosa Patient Needs and Perceived Treatment Benefits: An Explorative Study Using the Patient Benefit Index.

Authors:  Nicholas H B Schräder; Eva W H Korte; José C Duipmans; Roy E Stewart; Maria C Bolling; André P Wolff
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.